Literature DB >> 9101508

Direct medical costs unique to people with arthritis.

S E Gabriel1, C S Crowson, M E Campion, W M O'Fallon.   

Abstract

OBJECTIVE: We report the results of a population based analysis of all health services used and charges incurred over a one-year period among a community based cohort of persons with a diagnosis of arthritis [including both osteoarthritis (OA) and rheumatoid arthritis (RA)] compared to a similar cohort of individuals from the same community who have never had a diagnosis of arthritis (NA), to examine the attributable costs of this chronic condition.
METHODS: The unique resources of the Rochester Epidemiology Project were used to assemble the arthritis prevalence cohorts and the population based control cohort. The Olmsted County Health Care Utilization and Expenditures Database was used to collect information on health services utilization and charges.
RESULTS: The average direct medical charges for the RA, OA, and NA cohorts were $3,802.05, $2,654.51, and $1,387.83, respectively (age and sex adjusted, p < 0.0001 for both the RA vs NA and OA vs NA comparisons). The median charges for these 3 groups were $1,050.00, $663.55, and $232.04 for the RA, OA, and NA groups, respectively (age and sex adjusted p < 0.0001 for both the RA vs NA and OA vs NA comparisons). These analyses indicated that, compared to the NA cohort both the OA and the RA prevalence cohorts incurred statistically significantly more charges, not only for the musculoskeletal disease care, but also for the care of numerous other conditions including respiratory, cardiovascular, gastrointestinal, neurological, and psychiatric conditions; and for general medical care. Individuals with arthritis (both OA and RA) also incurred statistically significantly more charges for diagnostic and therapeutic procedures, in-hospital care, imaging studies, physician services, equipment, and laboratory studies. Use of prescription medications was statistically significantly more common in the RA and OA groups compared to NA (96.3, 96, and 83%, respectively; age and sex adjusted p = 0.006 for the OA vs NA comparison and p = 0.015 for RA vs NA).
CONCLUSION: These results emphasize the importance of considering all health services utilization (rather than only disease specific use) when estimating the economic effect of a chronic illness such as arthritis.

Entities:  

Mesh:

Year:  1997        PMID: 9101508

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  47 in total

1.  Degenerative musculoskeletal disease.

Authors:  O Ethgen; J-Y Reginster
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

Review 2.  Effects of exercise and physical activity on knee osteoarthritis.

Authors:  Stephan Esser; Allison Bailey
Journal:  Curr Pain Headache Rep       Date:  2011-12

3.  [Conceptual and methodological basics of cost assessments in rheumatology].

Authors:  J Ruof; J L Hülsemann; T Mittendorf; J-M von der Schulenburg; H Zeidler; S Merkesdal
Journal:  Z Rheumatol       Date:  2004-10       Impact factor: 1.372

Review 4.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Reduction of friction by recombinant human proteoglycan 4 in IL-1α stimulated bovine cartilage explants.

Authors:  Katherine M Larson; Ling Zhang; Khaled A Elsaid; Tannin A Schmidt; Braden C Fleming; Gary J Badger; Gregory D Jay
Journal:  J Orthop Res       Date:  2017-03-02       Impact factor: 3.494

Review 6.  Tai chi for osteoarthritis: a systematic review.

Authors:  Myeong Soo Lee; Max H Pittler; Edzard Ernst
Journal:  Clin Rheumatol       Date:  2007-09-14       Impact factor: 2.980

7.  Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

Authors:  Spencer B Jones; Lance A Pfeifer; Thomas J Bleisch; Thomas J Beauchamp; Jim D Durbin; V Joseph Klimkowski; Norman E Hughes; Christopher J Rito; Yen Dao; Joseph M Gruber; Hai Bui; Mark G Chambers; Srinivasan Chandrasekhar; Chaohua Lin; Denis J McCann; Daniel R Mudra; Jennifer L Oskins; Craig A Swearingen; Kannan Thirunavukkarasu; Bryan H Norman
Journal:  ACS Med Chem Lett       Date:  2016-08-02       Impact factor: 4.345

8.  Multidisciplinary and multifaceted outpatient management of patients with osteoarthritis: protocol for a randomised, controlled trial.

Authors:  Rikke Helene Moe; Till Uhlig; Ingvild Kjeken; Kåre Birger Hagen; Tore Kristian Kvien; Margreth Grotle
Journal:  BMC Musculoskelet Disord       Date:  2010-11-01       Impact factor: 2.362

Review 9.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

Review 10.  Glucosamine hydrochloride for the treatment of osteoarthritis symptoms.

Authors:  Beth Anne Fox; Mary M Stephens
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.